Verrica Pharmaceuticals Reports Strong Q1 2026 Growth on YCANTH Demand

Event summary

  • YCANTH dispensed applicator units grew 12.1% sequentially and 51.3% year-over-year to 15,302 in Q1 2026, exceeding 100,000 units since launch.
  • Total revenue reached $5.0 million, with U.S. YCANTH net product revenue up 16.2% sequentially and 25.4% year-over-year to $4.3 million.
  • YCANTH commercial launch in Japan by partner Torii Pharmaceutical represents expansion into first ex-U.S. market.
  • Over 50% of targeted enrollment achieved in the first trial of the global Phase 3 common warts program, with second trial expected to initiate in mid-2026.
  • Net loss remained at $9.7 million, but non-GAAP net loss per share improved to $0.41 from $0.88 in the same period last year.

The big picture

Verrica Pharmaceuticals is positioning itself as a leader in dermatological treatments, with YCANTH establishing itself as the standard of care for molluscum contagiosum. The company's expansion into Japan and the progress of its Phase 3 common warts program highlight its strategic focus on addressing significant unmet needs in dermatology. The broader industry trend of targeting dermatological conditions with innovative therapies underscores the potential for Verrica to capture a substantial share of this growing market.

What we're watching

Market Expansion
The pace at which YCANTH gains traction in Japan and other ex-U.S. markets will determine the success of Verrica's international strategy.
Clinical Development
The outcome of the Phase 3 common warts program will be critical in expanding YCANTH's market potential to an indication with an estimated 22 million patients in the United States.
Execution Risk
How Verrica manages its increasing commercial spend and research and development expenses will impact its ability to sustain growth and profitability.

Related topics

Pharmaceuticals